In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202403539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Haofei Hong und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, Chin…. Hauptthemen laut MEDLINE: Immunotherapy, Rituximab, Polyethylene Glycols, Rhamnose. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Enhancing the Fc effector functions of monoclonal antibodies (mAbs) is a proven strategy for improving cancer immunotherapy. In this study, we present a novel pre‐targeting approach that integrates host‐guest chemistry with an antibody‐recruiting concept to create mAbs with superior effector functions. Using rituximab (RTX), a clinically approved anti‐CD20 mAb, as our model, we modified RTX by conjugating it with adamantane (Ada) derivatives and various polyethylene glycol (PEG) linkers to produce RTX‐Ada conjugates. These conjugates effectively formed RTX‐rhamnose (Rha) complexes in situ through self‐assembly, driven by host‐guest interactions with Rha‐modified β‐cyclodextrin. This mechanism successfully redirected endogenous anti‐Rha antibodies to target cells, enhancing the availability of Fc domains for improved effector functions, including complement‐dependent cytotoxicity (CDC). A structure‐activity relationship study indicated that the potency of these in situ complexes was significantly influenced by the length of the PEG linker used; shorter PEG linkers correlated with higher CDC activity. Given the variability in endogenous antibody levels among individuals, this strategy presents a flexible and promising platform for enhancing the efficacy of mAb‐based cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, China.
ORCID-Profile: Zhimeng Wu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hong, H., Zhou, K., Lin, H., Li, Y., & Wu, Z. (2025). In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy. Chemistry – A European Journal. https://doi.org/10.1002/chem.202403539
Vancouver
Hong H, Zhou K, Lin H, Li Y, Wu Z. In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy. Chemistry – A European Journal. 2025. doi:10.1002/chem.202403539
BibTeX
@article{Hong2025,
author = {Hong, Haofei and Zhou, Kun and Lin, Han and Li, Yanchun and Wu, Zhimeng},
title = {In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202403539}
}
EUVIMED